<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/77558636-602F-416D-9BB4-73B783769BC3"><gtr:id>77558636-602F-416D-9BB4-73B783769BC3</gtr:id><gtr:name>Pfizer Ltd</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:department>Neuroscience Physiology and Pharmacology</gtr:department><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/77558636-602F-416D-9BB4-73B783769BC3"><gtr:id>77558636-602F-416D-9BB4-73B783769BC3</gtr:id><gtr:name>Pfizer Ltd</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/579B0578-3205-4CCD-BC64-F4619A787534"><gtr:id>579B0578-3205-4CCD-BC64-F4619A787534</gtr:id><gtr:firstName>Anthony</gtr:firstName><gtr:surname>Davies</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/A544B3F6-A07A-498E-9B7D-31D055013F58"><gtr:id>A544B3F6-A07A-498E-9B7D-31D055013F58</gtr:id><gtr:firstName>Annette</gtr:firstName><gtr:otherNames>Catherine</gtr:otherNames><gtr:surname>Dolphin</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/D8730E2E-B35E-41A8-8C6A-A07FC92FF6CA"><gtr:id>D8730E2E-B35E-41A8-8C6A-A07FC92FF6CA</gtr:id><gtr:firstName>Helen</gtr:firstName><gtr:surname>Saibil</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0100503"><gtr:id>EFC9AB0B-15CD-4611-8578-548A1F48FEE3</gtr:id><gtr:title>Studies on the functions and structure of neuronal calcium channel alpha2delta accessory subunits</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0100503</gtr:grantReference><gtr:abstractText>Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.</gtr:abstractText><gtr:fund><gtr:end>2007-09-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2002-10-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>1205397</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Pfizer Ltd</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>a2d subunit trafficking</gtr:description><gtr:id>25D7AF88-DC17-4581-AFA5-BAEBF0FF093C</gtr:id><gtr:impact>supports PhD studentship</gtr:impact><gtr:outcomeId>5285BF3B26A-1</gtr:outcomeId><gtr:piContribution>study of the mechanism of action of pregabalin</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>50000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Epilepsy Research UK Project Grant</gtr:description><gtr:end>2010-04-02</gtr:end><gtr:fundingOrg>Epilepsy Research UK</gtr:fundingOrg><gtr:id>A6B9CC4C-2B1C-456E-80F1-3F5387E4808E</gtr:id><gtr:outcomeId>643A54F65CC0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2008-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>80000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>PhD studentship</gtr:description><gtr:end>2011-10-02</gtr:end><gtr:fundingOrg>Pfizer Ltd</gtr:fundingOrg><gtr:id>44723613-02B1-44F7-8B2B-3ABCFA3E96B1</gtr:id><gtr:outcomeId>5B582BCFA2D0</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2008-11-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1029810</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Project Grant</gtr:description><gtr:end>2014-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>BF1D9F2C-B61B-435E-87BF-567DBECD6050</gtr:id><gtr:outcomeId>5350EDB68B80</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>778000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>BBSRC Project Grant</gtr:description><gtr:end>2010-10-02</gtr:end><gtr:fundingOrg>Biotechnology and Biological Sciences Research Council (BBSRC)</gtr:fundingOrg><gtr:id>B012926F-1237-4AC1-ACBB-46FDF9E40D49</gtr:id><gtr:outcomeId>B7E30C1EE0F0</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2007-10-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>cell lines containing alpha2delta2, both -HA tagged and non-tagged</gtr:description><gtr:id>2010B515-5885-46A5-A5A3-C1455673ABF6</gtr:id><gtr:impact>collaboration with Dr Roberto Chiesa</gtr:impact><gtr:outcomeId>E9C40D2C827</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>cell line</gtr:title><gtr:type>Cell line</gtr:type><gtr:yearFirstProvided>2009</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>antibodies to all calcium channel alpha2delta subunits</gtr:description><gtr:id>59407646-5A33-40F0-9C19-89AF78F7187B</gtr:id><gtr:impact>not known</gtr:impact><gtr:outcomeId>57DE252D673</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>antibodies</gtr:title><gtr:type>Antibody</gtr:type><gtr:yearFirstProvided>2006</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>D6171E36-B0E1-4C62-8F09-499210FBA2F8</gtr:id><gtr:title>The calcium channel alpha2delta-2 subunit partitions with CaV2.1 into lipid rafts in cerebellum: implications for localization and function.</gtr:title><gtr:parentPublicationTitle>The Journal of neuroscience : the official journal of the Society for Neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fa3532ffe1fc272856d4b64bfe31e1b0"><gtr:id>fa3532ffe1fc272856d4b64bfe31e1b0</gtr:id><gtr:otherNames>Davies A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0270-6474</gtr:issn><gtr:outcomeId>DAEF234B63E</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0D006F0B-F721-4A46-8BC0-FD5205463957</gtr:id><gtr:title>Do voltage-gated calcium channel alpha2delta subunits require proteolytic processing into alpha2 and delta to be functional?</gtr:title><gtr:parentPublicationTitle>Biochemical Society transactions</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c38712e8f5fd3ca8a09c1719f8f91ae6"><gtr:id>c38712e8f5fd3ca8a09c1719f8f91ae6</gtr:id><gtr:otherNames>Douglas L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0300-5127</gtr:issn><gtr:outcomeId>B1E98F76429</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A03EF3A2-7693-47CE-8C62-A50F7A97197C</gtr:id><gtr:title>Identification of the alpha2-delta-1 subunit of voltage-dependent calcium channels as a molecular target for pain mediating the analgesic actions of pregabalin.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b3fe2bab73205383e1dd3ddb8d178160"><gtr:id>b3fe2bab73205383e1dd3ddb8d178160</gtr:id><gtr:otherNames>Field MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>C588851FCCA</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>01B379A9-BD68-4582-A8D1-758FD4C76550</gtr:id><gtr:title>Genetic disruption of voltage-gated calcium channels in psychiatric and neurological disorders.</gtr:title><gtr:parentPublicationTitle>Progress in neurobiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7f7fcdf040221ef8e03e5d9050e40714"><gtr:id>7f7fcdf040221ef8e03e5d9050e40714</gtr:id><gtr:otherNames>Heyes S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0301-0082</gtr:issn><gtr:outcomeId>56c44249a3ac28.44814419</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>52751A92-CA90-431A-AE54-377C8FF0C5FF</gtr:id><gtr:title>The upregulation of a2d-1 subunit modulates activity-dependent Ca2+ signals in sensory neurons.</gtr:title><gtr:parentPublicationTitle>The Journal of neuroscience : the official journal of the Society for Neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bc01e708f5294b6931d75ae1a4832fdc"><gtr:id>bc01e708f5294b6931d75ae1a4832fdc</gtr:id><gtr:otherNames>D'Arco M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0270-6474</gtr:issn><gtr:outcomeId>doi_55f9859853b55ea4</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A20031B3-7B03-4044-80A4-531F0425FF17</gtr:id><gtr:title>The ducky(2J) mutation in Cacna2d2 results in reduced spontaneous Purkinje cell activity and altered gene expression.</gtr:title><gtr:parentPublicationTitle>The Journal of neuroscience : the official journal of the Society for Neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4a69d39a760f13543bb36510f71c0aca"><gtr:id>4a69d39a760f13543bb36510f71c0aca</gtr:id><gtr:otherNames>Donato R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0270-6474</gtr:issn><gtr:outcomeId>E54580F544D</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0B52D3FA-6D13-48C4-9F82-BEE54DF0EBD3</gtr:id><gtr:title>Pharmacological disruption of calcium channel trafficking by the alpha2delta ligand gabapentin.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/335ec006a30b9c5d839cd56ce8095689"><gtr:id>335ec006a30b9c5d839cd56ce8095689</gtr:id><gtr:otherNames>Hendrich J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>AE0794FE864</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7B366C4E-54DA-4956-83D7-E42136F0D9D4</gtr:id><gtr:title>Functional biology of the alpha(2)delta subunits of voltage-gated calcium channels.</gtr:title><gtr:parentPublicationTitle>Trends in pharmacological sciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fa3532ffe1fc272856d4b64bfe31e1b0"><gtr:id>fa3532ffe1fc272856d4b64bfe31e1b0</gtr:id><gtr:otherNames>Davies A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0165-6147</gtr:issn><gtr:outcomeId>0BCCC170826</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0100503</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>041997EB-CFD8-493D-B0F8-DFA35451D0BE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Neurological</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>